Second Department of Thoracic Surgery, Beijing Chest Hospital, Capital Medical University, Beijing, China.
Third Department of Thoracic Surgery, Beijing Chest Hospital, Capital Medical University, Beijing, China.
J Cancer Res Clin Oncol. 2023 Aug;149(9):6541-6548. doi: 10.1007/s00432-023-04616-2. Epub 2023 Feb 13.
Lung cancer is the most common form of cancer and the leading cause of cancer death. For familial lung cancer, identification of causing genetic factors is essential for prevention and control of non-lung cancer in carriers.
We studied two generations of a family with suspected inherited lung cancer susceptibility. Four individuals in this family had lung adenocarcinoma. To identify the gene(s) that cause the lung cancer in this pedigree, we extracted DNA from the peripheral blood of four cancer individuals and blood from three cancer-free family members as the control and performed whole-genome sequencing. Our filtering strategy includes, assessment of allele frequency, functional affection on amino acids, mutation accumulation, phased blocks and evolution analysis towards the alterations.
We identified two possible mutations, including PLEKHM2 (D134N) and MCC (R448Q) in all affected family members but did not found in the control group. Then, we performed a genetic susceptibility screening for 10 non-lung cancer relatives and found two individuals with PLEKHM2 (D134N) mutation, two with MCC (R448Q) mutation and one carrying both mutations. 3 carriers performed LDCT scan and 2 of them carried MCC (R448Q) also had ground-glass opacity (GGO) lesion in their lung.
Our data suggested that WGS together with our filtering strategy was successful in identifying PLEKHM2 (D134N) and MCC (R448Q) as the possible driver mutations in this family. Genetic susceptibility screening of non-lung cancer carriers will be a useful approach to prevent and control lung cancer in families with high-risk for the disease.
肺癌是最常见的癌症类型,也是癌症死亡的主要原因。对于家族性肺癌,确定致病遗传因素对于预防和控制携带者中非肺癌的发生至关重要。
我们研究了一个疑似遗传性肺癌易感性的家族的两代人。该家族中有 4 个人患有肺腺癌。为了确定该家系中导致肺癌的基因,我们从 4 名癌症个体的外周血和 3 名无癌症家族成员的血液中提取 DNA 作为对照,并进行全基因组测序。我们的筛选策略包括评估等位基因频率、对氨基酸的功能影响、突变积累、相位块和对改变的进化分析。
我们在所有受影响的家族成员中均发现了两个可能的突变,包括 PLEKHM2(D134N)和 MCC(R448Q),但在对照组中未发现。然后,我们对 10 名非肺癌亲属进行了遗传易感性筛查,发现 2 名个体携带 PLEKHM2(D134N)突变,2 名个体携带 MCC(R448Q)突变,1 名个体同时携带这两种突变。3 名携带者进行了 LDCT 扫描,其中 2 名携带 MCC(R448Q)的携带者肺部有磨玻璃样混浊(GGO)病变。
我们的数据表明,WGS 结合我们的筛选策略成功地确定了 PLEKHM2(D134N)和 MCC(R448Q)作为该家族中可能的驱动突变。对非肺癌携带者进行遗传易感性筛查将是预防和控制高危家族肺癌的有效方法。